Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Molecular and Cellular Biology|March 2, 2006
CARMA1 is required for Akt-mediated NF-kappaB activation in T cellsPreeti Narayan, Brittany Holt, Richard Tosti, et al.Anesthesia and Analgesia|April 1, 2014
The risk of hypertension after preoperative discontinuation of angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists in ambulatory and same-day admission patientsRebecca S Twersky, Vasudha Goel, Preeti Narayan, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 4, 2006
Cutting edge: inhibition of T cell activation by TIM-2Jared E Knickelbein, Anjali J de Souza, Richard Tosti, et al.Case Reports in Hematology|December 18, 2012
Primary myeloid sarcoma masquerading as an obstructing duodenal carcinomaPreeti Narayan, Vijayashree Murthy, Mu Su, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2023
US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast CancerPreeti Narayan, Asma Dilawari, Christy Osgood, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2025
US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast CancerSuparna Wedam, Preeti Narayan, Haley Gittleman, et al.The Oncologist|October 5, 2020
FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian CancerShaily Arora, Sanjeeve Balasubramaniam, Hui Zhang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2021
FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast CancerPreeti Narayan, Christy L Osgood, Harpreet Singh, et al.Clinical Pharmacology and Therapeutics|January 23, 2026
Emulating Comparative Oncology Trials With Real-World Evidence Studies (ENCORE): Process Development and Methodological Considerations for Oncology Real-World DataJanick Weberpals, Sebastian Schneeweiss, Kenneth L Kehl, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2021
U.S. FDA Drug Approvals for Breast Cancer: A Decade in ReviewShaily Arora, Preeti Narayan, Christy L Osgood, et al.Pageof 2